UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of January 2022

Commission File Number: 001-40241

LAVA Therapeutics N.V.

(Translation of registrant’s name into English)

Yalelaan 60

3584 CM Utrecht, the Netherlands

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  

 Form 20-F    Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  


EXHIBIT LIST

 

Exhibit

 

Description

99.1

LAVA Therapeutics N.V. Investor Presentation.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

LAVA Therapeutics N.V.

Date: January 7, 2022

 

 

By:

 

/s/ Edward F. Smith

 

 

 

Name

Edward F. Smith

 

 

 

Title:

 

Chief Financial Officer


LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more LAVA Therapeutics NV Charts.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more LAVA Therapeutics NV Charts.